Squarepoint’s Idexx Laboratories IDXX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$261K Sell
500
-800
-62% -$438K ﹤0.01% 3897
2026
Q2
$684K Buy
+1,300
New +$729K ﹤0.01% 3184
2025
Q4
– Sell
-5,000
Closed -$3.19M – 4540
2025
Q3
$3.19M Buy
5,000
+3,100
+163% +$1.88M ﹤0.01% 1739
2025
Q2
$1.02M Buy
+1,900
New +$909K ﹤0.01% 2639
2024
Q3
– Sell
-800
Closed -$390K – 4359
2024
Q2
$390K Sell
800
-1,400
-64% -$703K ﹤0.01% 3255
2024
Q1
$1.19M Buy
+2,200
New +$1.2M ﹤0.01% 2468

Other funds holding IDXX

Squarepoint's IDXX Position: Q3 2026 in Review

Squarepoint reduced its Idexx Laboratories (IDXX) stake by 31% in Q3 2026, selling an estimated $53.5M and leaving 217,528 shares worth $114M. The position accounts for 0.13% of the portfolio, ranked #139.

Squarepoint first reported a position in IDXX in Q1 2015 and has held it in 36 quarters since. The position peaked at $166M in Q2 2026. 804 funds tracked by Wall St. Rank hold IDXX as of Q3 2026.

  • Squarepoint held 217,528 shares of Idexx Laboratories worth $114M as of Q3 2026.
  • Squarepoint sold 97,636 Idexx Laboratories shares in Q3 2026, an estimated $53.5M.
  • Idexx Laboratories made up 0.13% of Squarepoint's portfolio in Q3 2026, its #139 holding.
  • Squarepoint first reported a position in Idexx Laboratories in Q1 2015 and has held it in 36 quarters since.
  • Squarepoint's Idexx Laboratories position peaked at $166M in Q2 2026.
  • 804 funds tracked by Wall St. Rank held Idexx Laboratories as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.